Prevention of Reperfusion Injury in Myocardial infarction (PRIME) trial

Phase 1

• Conditions: ST-Elevation Myocardial Infarction; Cardiovascular - Coronary heart disease

• Registration Number: ACTRN12624000409572
• Lead Sponsor: Te Whatu Ora Waikato

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2024-04-04
• Last Update Posted: 8 April 2024

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

Patients presenting to Waikato Hospital with acute ST-Elevation Myocardial Infarction (STEMI) on Electrocardiogram (ECG), as interpreted by Emergency Department (ED) or Cardiology Senior Medical Officer (SMO) or Senior Registrar.
The patient will then be discussed with the on-call Cardiac interventionalist, if the best treatment for the patient is judged to be primary percutaneous intervention (PCI) within the next 4 hours, the enrollment process can then be started.

Exclusion Criteria

Allergy to Paracetamol
Known liver failure (Child-Pugh class C)
GCS less than 15
Unable to swallow tablets – ie. intubated or too medically unwell to safely swallow tablets.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Peak troponin level[Highest serum troponin level taken during patients recovery after PCI Day 1, 2, 3, 4 post PCI]

Secondary Outcome Measures

Name	Time	Method
Incidence of ventricular arrhythmia[Continuous cardiac monitoring Continuous monitoring during the patients stay in hospital of Day 1, 2, 3, 4 post PCI.];30-day Mortality rate[Incidence of death within 30 days of recruitment to the trial Day 30 post PCI];left ventricular ejection fraction[echocardiogram prior to discharge from hospital]